CybeRelease: (OTC: KALG) Rated ’Speculative Buy’ Rating, Target Price $2.00 by Beacon Equity Research

(CybeRelease, April 19, 2007) – Lake Harmony, Pa. - KAL Energy (OTC BB: KALG) has been rated “Speculative Buy” with a target price of $2.00 by Beacon Equity Research Analyst, Lisa Springer, CFA.

The full report is available at http://www.BeaconEquityResearch.com
Anyone interested in receiving alerts regarding KAL Energy research should email members@beaconequityresearch.com with “KALG” in the subject line.

In the report, the analyst writes, "KAL Energy, Inc. is a junior exploration stage coal mining company. The Company, through its wholly owned subsidiary, Thatcher Mining Pte. Ltd., owns two coal concessions near the Mahakam River in North Eastern Kalimantan, Indonesia. The location of the coal concessions offers easy access to the ocean and opportunities to ship coal to markets in India, and North and Southeast Asia. Initial analysis of the coal concessions indicates reserves may exceed 192 million tons. The Company has secured funding for Phase I of its $2 million development plan, has commenced drilling at its coal properties to determine the grade and tonnage of coal, and plans to complete Phase I of drilling by the second quarter of 2007.
“We feel the Company’s high projected growth rate compared to that of its peers justifies a valuation at the higher end of the range. By the time annual production reaches 15 million tons, KAL could be valued at nearly $700 million, or $8.50 per share, based on a one time Price/Sales multiple and revenues of $675 million.”

Other publicly traded coal producing companies includes Foundation Coal Holding (NYSE:FCL - News), Allied Resource Partners (NASDAQ:ARLP - News), Alpha Natural Resources (NYSE:ANR - News) and Arch Coal (NYSE:ACI - News).

To read the complete release, go to http://biz.yahoo.com/bw/070419/20070419005286.html?.v=1.

CybeRelease Gainers are Intersil Corporation (Nasdaq: ISIL), Gilead Sciences, Inc. (Nasdaq: GILD), Columbia Laboratories, Inc. (Nasdaq: CBRX), Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), Alvarion Ltd. (Nasdaq: ALVR), Aspreva Pharmaceuticals Corporation (Nasdaq: ASPV), Ryanair Holdings PLC (Nasdaq: RYAAY) and Frontier Airlines, Inc. (Nasdaq: FRNT).

CybeRelease Decliners are Novellus Systems, Inc. (Nasdaq: NVLS), Spansion Inc. (Nasdaq: SPSN), Avici Systems Inc. (Nasdaq: AVCI), Smith Micro Software, Inc. (Nasdaq: SMSI), Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), Logitech International S.A. (Nasdaq: LOGI), Compuware Corporation (Nasdaq: CPWR) and Cell Genesys, Inc. (Nasdaq: CEGE).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $995.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.

Contact Information

C. P. Barry

Media Contact

CybeRelease.com

Contact via E-mail